Herantis Pharma Plc, Company release, 2 June 2021 at 9:30 AM EEST
Herantis Pharma Plc (“Herantis or the Company”), focusing on disease modifying therapies for debilitating neurodegenerative diseases, announced today that the company was featured in the annual publication of Nature Magazine's BioPharma Dealmakers June 2021 edition which focuses on the latest developments in CNS.
The Herantis article, titled, Protecting the proteome from Parkinson’s disease, details how Herantis is capitalizing on the power of the natural protein Cerebral Dopamine Neurotrophic Factor (CDNF) to restore proteostasis and slow, stop, or even reverse neurodegeneration.
The complete article is available in print and in digital format and can be viewed via the following link: www.nature.com/articles/d43747-021-00070-6
For more information, please contact:
Julie Silber/Gabriela Urquilla
Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19
Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225, Sweden: +358 40 5161400
Company website: www.herantis.com
About Nature – Biopharma Dealmakers
Nature, a well known, bi-weekly multidisciplinary publication that features the finest peer-reviewed research from a variety of academic disciplines mainly in science and technology, produces Biopharma Dealmakers, a Research publication that brings together life scientists, biotech and pharmaceutical professionals, and investors from across the globe. Biopharma Dealmakers provides timely information and analysis on that gives insights into dealmaking and industry trends. Regular editorial content includes biopharma deal round-ups, financing news and a collection of ‘business of science’ articles from the Nature Research catalogue.
About Herantis Pharma Plc
Herantis focuses on disease modifying therapies for debilitating neurodegenerative diseases by restoring the neuronal protective mechanism of proteostasis, a key system in neurodegenerative disease. Proteostasis regulates proteins within the body and influences the fate of every protein from synthesis to degradation. Its failure results in a vicious cycle of pathological accumulation of protein aggregates, neuroinflammation and various forms of cellular stress that is widely implicated with the development of many neurodegenerative diseases including Parkinson’s Disease, Alzheimer’s and other diseases. CDNF is a protein that occurs naturally in the body whose normal role is to protect neurons by balancing and supporting proteostasis, thereby preventing and counteracting disease generating mechanisms. Herantis is taking this natural ability and harnessing it as a treatment for neurodegenerative disease. CDNF – a biological protein – is Herantis’ lead program and a clinical stage asset; and xCDNF – a synthetic peptide version of CDNF – is Herantis’ follow-on program. Both CDNF and xCDNF have, via their multimodal mechanism of action, the potential improves neuronal survival and to stop the progression of Parkinson’s and other neurodegenerative disease and have a significant therapeutic impact on the lives of patients.
The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden. For more information, please visit https://www.herantis.com